Mosliciguat clinical trials
How each study uses mosliciguat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mosliciguat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test mosliciguat.
- Dec 2026A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILDPhase 2 · Pulmovant, Inc.
Studies
Open first, then newest update. How each study uses mosliciguat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)RecruitingPhase 3Pulmovant, Inc.NCT07816185Written as Mosliciguat
- A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILDRecruitingPhase 2Pulmovant, Inc.NCT07333183Written as inhaled mosliciguat
- A Study of Mosliciguat in PH-ILDActive, not recruitingPhase 2Pulmovant, Inc.NCT06635850Written as Mosliciguat
- A Phase 1 Study of Mosliciguat in Healthy, Adult MalesCompletedPhase 1Pulmovant, Inc.NCT07185321Written as Mosliciguat
- This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)CompletedPhase 1BayerNCT03754660Written as BAY1237592
Codes
What other systems call mosliciguat · ClinicalTrials.gg INT016570
- UNII (FDA) FL039XI4KFMOSLICIGUATConfirmed FDA, Wikidata
- Wikidata Q123663269mosliciguatConfirmed FDA, Wikidata
- NCI Thesaurus C175826MosliciguatOne source FDA
- DrugBank DB19425One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FL039XI4KF | MOSLICIGUAT | Confirmed FDA, Wikidata |
| Wikidata | Q123663269 | mosliciguat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175826 | Mosliciguat | One source FDA |
| DrugBank | DB19425 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.